Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2341 participants.
Also called NCT01507831
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,341 participants
- Sponsor
- Registry
-
NCT01507831 -
2011-002806-59
-
- Other papers using this trial's data
- Efficacy and safety of alirocumab in reducing lipids and cardiovascular events
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Belgium, Bulgaria, Canada, Chile, Colombia, Czechia, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Russia, South Africa, Spain, Sweden, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01507831. Randomized; quadruple masking; primary purpose treatment. Start 2012-01 (registry gives no type); primary completion 2014-11 (actual). Results posted on 2015-12-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- Placebo (for alirocumab)
- Intervention (Drug)
- Alirocumab
- Intervention (Drug)
- Lipid-Modifying Therapy (LMT)
- Lead sponsor
- Sanofi
- Collaborator
- Regeneron Pharmaceuticals
Record details
- Record id
cardio:ct-nct01507831- Content hash
df6fbd33ce3d0d7520413e98bd1868fb1f0f4eeff731834423b1ab80ab31934e